Prognosing survival time of patient with pancreatic carcinoma after diagnosis comprises determining quantity of gene product/methylation state of regulatory region of gene, comparing expression vector with existing data set and calculating

摘要

Method for prognosis of survival time of patients with pancreatic carcinoma disease after diagnosis comprises: (a) determining a quantity of gene product and/or methylation state of regulatory region of at least three genes comprising genes (as given in tables (1-4) of the specification) in a sample of biological material of a patient, (b) preparing an expression vector of the patient, (c) comparing the expression vector of the patients with an existing data set, and (d) calculating the expected value of lifetime for the patient after diagnosis. Method for prognosis of survival time of patients with pancreatic carcinoma disease after diagnosis, comprises: (a) determining a quantity of gene product and/or methylation state of regulatory region of at least three genes comprising genes (as given in tables (1-4) of the specification) in a sample of biological material of a patient, (b) preparing an expression vector of the patient, where the expression vector contains genes and respective quantity of a gene product and/or methylation state, (c) comparing the expression vector of the patients with an existing data set, where the existing data set comprises an expression matrix with genes and the respective amounts of a gene product and/or the methylation state and the achieved lifetime of the patients after diagnosis and (d) calculating the expected value of lifetime for the patient after diagnosis, from the comparison of the expression vector of the patient with the existing data set. An independent claim is included for a diagnostic kit for the prognosis of survival time of patients with pancreatic carcinoma disease after diagnosis, comprising (i) at least three different primer pairs for real time-PCR, where the primer pairs are specifically hybridized with each cDNA of genes (as given in tables (1-4, preferably 5) of the specification), each primer pair is hybridized with respective cDNA of other gene (as given in tables (1-4) of the specification) and the primer pair is optionally a DNA polymerase, preferably Thermus aquaticus polymerase, which is stable at above 80[deg] C, (ii) a microarray chip containing at least three oligonucleotides that are specifically hybridized with each cDNA of genes (as given in tables (1-4, preferably 5) of the specification), where each oligonucleotide is hybridized with respective cDNA of other gene (as given in tables (1-4) of the specification), (iii) at least three antibodies or high-affinity molecules that specifically bind to a protein or protein fragment encoded by one of the genes (as given in tables (1-4, preferably 5) of the specification), where the antibodies or high-affinity molecules are directed against each different proteins or protein fragments, and (iv) nucleic acid-modifying chemicals, preferably bisulfite, and/or a methylation-sensitive restriction endonuclease and at least three different primer pairs, where each of the primer pairs is suitable for the amplification of at least a cytosine-phosphate-guanine (CpG)-position of a regulatory region of a gene (as given in tables (1-4, preferably 5) of the specification) and optionally a reaction buffer.